// App-Quantinova.ai

: Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Researchers

Presenter

  • Matthias Stelljes

Principal Investigators

  • Ralph Wasch

  • Sebastian Scholl

  • Kathrin Nachtkamp

  • Andreas Rank

  • Mathias Haenel

  • Bernd Spriewald

  • Maher Hanoun

  • Sonja Martin

  • Katjana Schwab

  • Julian Knaden

  • Lena Reiser

  • Julia Marx

  • Klaus Wethmar

  • Tim Sauer

  • Wolfgang E. Berdel

  • Georg Lenz

  • Monika Bruggemann

  • Simon Raffel

  • Nicola Goekbuget

Medical Centers

  • Medical Clinic II, University Hospital of Augsburg, Augsburg, Germany

  • Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany

  • Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany

  • University of Frankfurt, Frankfurt, Germany

  • Med. Klinik / Hämatologie u. Internist. Onkologie, Universität Erlangen-Nürnberg, Erlangen, Germany

  • German Cancer Reseach Center, Heidelberg, Germany

  • University Hospital Jena, Jena, Germany

  • Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany

  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany

  • University of Bonn, Bonn, Germany

  • Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany

  • Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany

  • Department of Hematology, Oncolog and Pneumology, University of Münster, Münster, DEU

  • Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany

  • University Hospital TU Dresden, Germany, Dresden, Germany

  • Klinikum Chemnitz, Chemnitz, Germany

  • Department of Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • Cytarabine liposomal

  • Rituximab

  • 6-mercaptopurine

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved